Ismail Elalamy

TL;DR: COVID‐19 infected patients, whether hospitalized or ambulatory, are at high risk for venous thromboembolism, and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended.

TL;DR: An expert consensus statement on the prophylaxis and management of VTE associated with COVID-19 is developed and provides practical recommendations in detailed situations, for example, how to choose thromboprophylactic measures for patients with diverse severity of disease and bleeding risk, or which kind of anticoagulant should be prescribed.

TL;DR: All patients at moderate to high risk for the development of venous thrombo- embolism should receive prophylaxis, and the approaches of proven value include low-dose heparin, low molecular weight heparins, oral anticoagulants and intermittent pneumatic compression.

TL;DR: The aim of this document is to provide a clear and concise account of the evidence regarding efficacy or harm for various methods available to prevent and manage venous thromboembolism (VTE).

TL;DR: High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome.